CS
GPCR icon

Candriam SCA’s Structure Therapeutics GPCR Stock Holding History

Candriam SCA’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-214,063
Closed -$3.71M – 696
2025
Q1 		$3.71M Sell
214,063
-1,358
-0.6% -$33.3K 0.02% 391
2024
Q4 		$5.84M Buy
215,421
+80,421
+60% +$2.85M 0.03% 332
2024
Q3 		$5.92M Hold
135,000
– – 0.03% 335
2024
Q2 		$5.3M Hold
135,000
– – 0.03% 334
2024
Q1 		$5.79M Sell
135,000
-75,000
-36% -$3.16M 0.04% 322
2023
Q4 		$8.56M Buy
+210,000
New +$12M 0.06% 272

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA's GPCR Position: Q2 2025 in Review

Candriam SCA sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 214,063 shares — an estimated $3.71M sold.

Candriam SCA first reported a position in GPCR in Q4 2023 and held it in 6 quarters. The position peaked at $8.56M in Q4 2023. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

  • Candriam SCA reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Candriam SCA sold 214,063 Structure Therapeutics shares in Q2 2025, an estimated $3.71M.
  • Candriam SCA first reported a position in Structure Therapeutics in Q4 2023 and held it in 6 quarters.
  • Candriam SCA's Structure Therapeutics position peaked at $8.56M in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.